This study will determine the following: the response rate (including pathological CR rate),
TTP, and complications of treatment in patients with rectal cancer treated with FOLFOX
bevacizumab, the alteration of tumor blood flow (assessed by DCE-MRI as percentage change in
Ktrans) after 1 cycle of bevacizumab therapy compared to baseline value in patients treated
with FOLFOX alone and those treated with bevacizumab at 5 mg/kg., the degree of hypoxis
(measured by tumor uptake of the 2-nitroimidazole EF5) induced by bevacizumab treatment and
its relationship to changes in tumor blood flow, and the degree of apoptosis (measured by
tumor uptake of di-annexin V) induced by bevacizumab treatment and its relationship to
changes in tumor blood flow.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania